Promising vaccines for treating glioblastoma.
Adam M SwartzSteven H ShenMiguel A SalgadoKendra L CongdonLuis Sanchez-PerezPublished in: Expert opinion on biological therapy (2018)
To date, no cancer vaccines have been proven effective against GBM; however, only a few have reached phase III clinical testing. Clinical immunological monitoring data suggest that GBM vaccines are capable of stimulating immune responses reactive to GBM antigens, but whether these responses have an appreciable antitumor effect on GBM is still uncertain. Nevertheless, there have been several promising outcomes in early phase clinical trials, which lend encouragement to this area of study. Further studies with GBM vaccines are, therefore, warranted.
Keyphrases
- clinical trial
- phase iii
- immune response
- open label
- papillary thyroid
- phase ii
- randomized controlled trial
- squamous cell carcinoma
- type diabetes
- electronic health record
- double blind
- metabolic syndrome
- insulin resistance
- skeletal muscle
- machine learning
- big data
- squamous cell
- study protocol
- lymph node metastasis
- placebo controlled